Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 8;13:948335. doi: 10.3389/fimmu.2022.948335

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Garcia-Dominguez, Henry, Ma, Jani, Amato, Manning, Freyn, Davis, Hsiao, Li, Koch, Elbashir, DiPiazza, Carfi, Edwards and Bahl

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Study Design. The impact of the dosing interval on mRNA-1273 vaccine immunogenicity was evaluated by administering 2 doses of mRNA-1273 (1 µg or 10 µg) to mice on a schedule of 1-, 2-, 3-, 4-, 6-, or 8-week intervals between doses; a prime-only group (only administered first dose of mRNA-1273 at time of dose 2) was also evaluated for comparison purposes. Sera were collected from mice (n=8-10 per group) before dose 2 and 1, 2, 4, 8, 12, 16, 20, and 24 weeks following dose 2. Spleens were collected 1, 4, 12, and 24 weeks after dose 2 from a subgroup of mice (n=8-10 per group) administered mRNA-1273 10 µg; bone marrow samples were collected 2 and 24 weeks after dose 2 from the same subgroup of mice. mRNA, messenger RNA.